Literature DB >> 2465910

Immunohistochemical analyses of oncocytic and chromophobe pituitary adenomas.

H J Günzl1, W Saeger, S Diehl, D K Lüdecke.   

Abstract

Immunohistochemical analyses using antibodies against the major pituitary hormones, the alpha-subunit of glycoprotein hormones, chromogranin and synaptophysin were performed on 10 adenomas with oncocytic parts (26%-50% oncocytes, Group I), on 9 oncocytic adenomas with 51%-75% oncocytes (Group II), and on 12 oncocytic adenomas with 76%-100% oncocytes (Group III). Only 11 of the 31 investigated adenomas (35%) showed negative immunostaining for all major anterior pituitary hormones. FSH-content could be shown in 16 of 31 adenomas (52%), LH-content in 12 of 31 adenomas (39%), TSH-content in 3 of 31 adenomas (10%). Comparing all three groups of adenomas, there are no differences in the immunoreactivity to alpha-subunit (24 of 31 adenomas, 77%), chromogranin (26 of 31 adenomas, 84%), and of synaptophysin (13 of 31 adenomas, 42%). Considering the high percentage of cells of oncocytes showing alpha-subunit immunoreactivity we regard oncocytomas as originating very often from TSH-gonadotropin cell complexes of the anterior hypophysis. Alpha-subunit might become a reliable marker for oncocytomas. The finding of immunoreactivity to chromogranin in most cases confirms morphological studies that oncocytes contain some secretory granules. In most cases, the studied oncocytomas did not react to synaptophysin showing different results from other adenomas of the anterior hypophysis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2465910     DOI: 10.1055/s-0029-1210781

Source DB:  PubMed          Journal:  Exp Clin Endocrinol        ISSN: 0232-7384


  2 in total

Review 1.  Human pituitary adenomas. Recent advances in morphological studies.

Authors:  G Giannattasio; M Bassetti
Journal:  J Endocrinol Invest       Date:  1990-05       Impact factor: 4.256

2.  Pituitary oncocytomas: clinical features, characteristics in cell culture, and treatment recommendations.

Authors:  D L Silbergeld; M R Mayberg; M S Berger; F Ali-Osman; W A Kelly; C M Shaw
Journal:  J Neurooncol       Date:  1993-04       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.